GTC is proud to announce its 2nd Immunogenicity and Immunotoxicity Conference, one of four parallel tracks to the Novel Immunotherapeutics Summit 2014 on January 30 – 31, 2014 in San Diego, CA. The conference will cover important progress made in the areas of therapeutic protein immunogenicity and immunotoxicity evaluation such as protein aggregation, clinical relevance and assessment of immunogenicity, mitigation of immunogenicity-related risks, biosimilar development, and immunotoxicity evaluation strategies.
The Immunogenicity and Immunotoxicity Conference will provide guests with a better understanding of the ongoing research for tools to mitigate risks associated with the immunogenicity of therapeutic proteins. Guests will get an up-to-date understanding of the mechanisms and consequences of protein aggregation and insights on how to prosecute state-of-the-art assessment of the clinical immunogenicity of therapeutic proteins.
Sessions for 2014 include:
I. Immunotoxicity Evaluation of Novel Drug Candidates
II. Protein Aggregation Biological Activity and Immunogenicity
III. Immunogenicity Assessment for Biosimilars
IV. Immunogenicity Prediction, Causes, Mitigation and Strategies
V. Risk Assessment and Management
VI. Clinical Relevance of Immunogenicity
VII. Immunotoxicity and Drug Hypersensitivity
VIII. ADC and Immunogenicity
To view 2014 agenda, click here.
To view 2014 speaker list, click here.
Contacts:
- Global Technology Community
- 635 W. Foothill Blvd, Monrovia, CA 91016
- phone: 626-256-6405
- fax: 626-466-4433
- email: [email protected]